Seffiline | Mamacrowd

TAX Bonus

Innov STARTUP

Watch the video

Seffiline

Medical Devices

Devices for performing regenerative medicine therapies in a safe, simple, standardized and effective manner.

  • The regenerative therapy market is booming

  • Great dissemination potential for ease of use

  • Significant corporate assets of intellectual property

  • The devices can be used in many medical specialties

Professional Investor

Professional Inv.

min: 149.997 €

OVERFUNDING New max: 600.092 €

77 Investments

412.476 €

77 Paid

412.475 €

Minimum goal

149.997 €

Minimum Order

499,84 €

Pre-Money

2.997.620 €

09.12.2021

Closed

The content of this page has been translated automatically

Project

Autologous regenerative therapy with adipose-derived mesenchymal stem cells has for years been a technology consideredcutting-edge and supported by enormous scientific production. In 2015, Prof. Alessandro Gennai published a surgical technique called S.E.F.F.I., which is receiving enormous interest in the surgical field because it greatly reduces the need for manipulation of harvested adipose tissue, thus safeguarding the viability of the cells to be implanted.

Some medical devices are already on the market, but they all have critical issues that do not allow their practical use except by highly qualified surgeons because they require experience in harvesting subcutaneous adipose tissue.

SEFFILINE was established in 2018 with the goal of making autologous regenerative therapy accessible to all physicians for application in various specialties. Through the invention of the guide, which was immediately patented, the goal is achieved.

In 2019, production and sale of the first and only medical device enabling autologous regenerative therapy through the use of mesenchymal stem cells of adipose origin begins. The device is all-in-one, disposable, standardized, safe and inexpensive, and can be used in medical clinics, without the need for an operating room and expensive machinery, by physicians of any specialty and without specific expertise in harvesting adipose tissue.

The regenerative potential of adipose-derived mesenchymal stem cells is extremely vast, enabling a variety of applications. Therefore, SEFFILINE has made medical devices that enable regenerative therapy in various fields:

  • Seffiller in Aesthetic Medicine for anti-aging facial treatment
  • Seffihair in Tricology for prevention and treatment of hair loss
  • Seffigyn in Gynecology for intimate well-being in childbearing and menopause and against genito-urinary syndrome
  • Sefficare in Orthopedics for the treatment of joint pathologies, including in sportsmen; in Vulnology for the treatment of sores and complex wounds; in Dermatology for the treatment of skin pathologies; and in other fields such as Vascular Surgery, Plastic Surgery, Urology, Colonproctology, and Otolaryngology to assist tissue regeneration.

SEFFILINE has entered into exclusive distribution agreements with minimum sales contractual constraints in the following countries: Italy, United Kingdom, Australia, New Zealand, United Arab Emirates and Saudi Arabia, Indonesia, Philippines and Thailand, Brazil while contacts are in place with Poland, Spain, Germany, France, Ukraine, Israel, Jordan, Mexico, Turkey, and Russia.

At present, most of the distributors are in the process of approving products in their respective countries and training agents. SEFFILINE, through its Academy, is in charge of the selection and training of trainers, medical opinion leaders and 'ambassadors' who train medical end-customers.

20210927190938_9c00ded7_Seffiline%20Slide%20Corredo%2002%201280x720

Do you want to find out more about this project?

Do you already have an account?

The information on the offer is not subject to approval by Consob. The Offering company is solely responsible for the completeness and truthfulness of the data and information provided by the latter. The investor's attention is also drawn to the fact that the investment, even indirect, through OICR or companies that invest mainly in financial instruments issued by innovative startups and SMEs is illiquid and characterised by a very high risk.